PMC:7534795 / 1479-1815
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T13 | 251-259 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T23 | 120-125 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T24 | 136-147 | Chemical | denotes | metabolites | http://purl.obolibrary.org/obo/CHEBI_25212 |
| T25 | 182-187 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T26 | 201-209 | Chemical | denotes | adjuvant | http://purl.obolibrary.org/obo/CHEBI_60809 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T57624 | 317-329 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T10 | 71-269 | Sentence | denotes | Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 41 | 260-268 | Species | denotes | patients | Tax:9606 |
| 49 | 116-125 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 50 | 178-187 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 61 | 251-259 | Disease | denotes | COVID-19 | MESH:C000657245 |